Translational Metabolic Physiology GLP-1 Jens Juul Holst – University of Copenhagen

Translational Metabolic Physiology

Section for Translational Metabolic Physiology

In our Section, major research goals are centred around the hormones Glucagon-Like Peptide-1 (GLP-1), which was discovered in our laboratory and has been studied extensively by the Section (analogues are now available for diabetes and obesity treatment); Glucagon-like peptide-2, a regulator of intestinal growth and function as well as bone metabolism (also discovered in our lab, and recently approved for treatment of short-bowel syndrome); Glucose dependent Insulinotropic polypeptide (GIP), also a regulator of bone and insulin secretion and fat deposition; PYY (a powerful inhibitor of food intake); neurotensin (another appetite suppressant); and glucagon, essential for both glucose and protein metabolism.

Major goals also include elucidation of the beneficial effects of gastric bypass surgery on both diabetes and obesity, and understanding the mechanisms at the organ, cellular and molecular level that cause exaggerated secretion of the gut hormones after bypass surgery with a view to reproduce this in future therapeutic strategies..